EZH2 and acute myeloid leukemia: Risk stratification groups were then reclassified as favorable risk (ie, mutant NPM1 and DDX41 and wild-type TP53, KRAS, and EZH2), intermediate risk (not classified as favorable or adverse risk), and adverse risk (mutant TP53, KRAS, and EZH2) as the “Beat AML genetic risk model” for HMA + VEN (supplemental Figure 2), with a median OS of not reached, 16.8 months, and 9.9 months for favorable, intermediate, and adverse risk, respectively (P < .001; C-index, 0.586; Figure 1C).